No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Dr. Reddy's Laboratories Limited, along with its various subsidiaries, functions as a globally integrated pharmaceutical enterprise. Its operations are structured into three primary business divisions: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and 'Others'. The Global Generics segment is responsible for the production and commercialization of both prescription and over-the-counter (OTC) finished pharmaceutical products. These offerings are marketed either under proprietary brand names or as generic formulations that are therapeutically equivalent to their branded counterparts. This division also has a presence in the biologics sector. The PSAI segment focuses on the manufacturing and distribution of active pharmaceutical ingredients (APIs) and chemical intermediates, which are essential components for finished drug products. Additionally, this division provides contract research services and undertakes the custom manufacturing and sale of APIs and steroids to meet specific customer requirements. Within the 'Others' segment, the company is involved in developing novel therapies for oncology and inflammatory conditions, conducting research and development for distinctive pharmaceutical formulations, and offering digital healthcare alongside IT-enabled business support services. Dr. Reddy's Laboratories addresses a broad range of therapeutic areas, including gastrointestinal, cardiovascular, anti-diabetic, dermatological, oncological, respiratory, stomatological, urological, and nephrological conditions. Established in 1984, the company's corporate headquarters are located in Hyderabad, India.
www.drreddys.comNo one on the platform currently holds DRREDDY.BO.
No tracked institution reports a position in DRREDDY.BO as of their last filing.
No one on the platform has traded DRREDDY.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.0% | 13.7% | 10.9% | — | — | — |
| Rev. Growth % | 3.2% | 12.1% | ||||
| Profit Margin % | 12.8% | 15.9% | 12.7% | |||
| Free Cash Flow Margin % | 9.1% | 8.4% | 7.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $350.9B | +2.2% | $42.99 | $32.79–$51.73 | — | 32 |
| 2028 | $392.1B | +11.7% | $56.52 | $52.13–$67.75 | — | 16 |
| 2029 | $431.8B | +10.1% | $68.98 | $63.62–$82.68 | — | 25 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-21 | $8.75 | $5.33 | -39.1% |
| 2026-05-11 | $11.06 | $2.64 | -76.1% |
| 2026-01-20 | $13.76 | $14.52 | +5.5% |
| 2025-10-24 | $16.99 | $17.25 | +1.5% |
| 2025-07-23 | $18.38 | $17.02 | -7.4% |
| 2025-05-09 | $18.18 | $19.11 | +5.1% |
| 2025-01-23 | $17.87 | $16.94 | -5.2% |
| 2024-11-05 | $16.98 | $15.05 | -11.4% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| DRREDDY.BODr. Reddy's Laboratories Limited | $1152.75 | -0.71% | $968.5B | — |
| ALKEM.BOAlkem Laboratories Limited | $5284.55 | +3.83% | $630.9B | — |
| ALKEM.NSAlkem Laboratories Limited | $5277.00 | +3.72% | $630.9B | — |
| AUROPHARMA.BOAurobindo Pharma Limited | $1665.00 | -0.62% | $957.6B | — |
| AUROPHARMA.NSAurobindo Pharma Limited |
| $1671.70 |
| -0.48% |
| $961.9B |
| — |
| LUPIN.BOLupin Limited | $2073.00 | -1.10% | $945.3B | — |
| LUPIN.NSLupin Limited | $2074.60 | -0.97% | $948.6B | — |
Source: Financial Modeling Prep · peers by sector/industry